209 related articles for article (PubMed ID: 32339362)
1. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.
Carugno A; Raponi F; Locatelli AG; Vezzoli P; Gambini DM; Di Mercurio M; Robustelli Test E; Sena P
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e433-e434. PubMed ID: 32339362
[No Abstract] [Full Text] [Related]
2. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.
Ferrucci S; Romagnuolo M; Angileri L; Berti E; Tavecchio S
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e303-e304. PubMed ID: 32330323
[No Abstract] [Full Text] [Related]
3. Hair regrowth and dissemination of molluscum contagiosum: two unexpected effects with dupilumab.
Sevray M; Dupré D; Misery L; Abasq-Thomas C
J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):e296-e298. PubMed ID: 30875133
[No Abstract] [Full Text] [Related]
4. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.
Rossi M; Rovati C; Arisi M; Soglia S; Calzavara-Pinton P
Dermatol Ther; 2020 Jul; 33(4):e13765. PubMed ID: 32500660
[No Abstract] [Full Text] [Related]
5. Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.
Benzecry V; Pravettoni V; Segatto G; Marzano AV; Ferrucci S
J Investig Allergol Clin Immunol; 2021 Jun; 31(3):261-263. PubMed ID: 32732182
[No Abstract] [Full Text] [Related]
6. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
7. Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab.
Storan ER; Woolf RT; Smith CH; Pink AE
Br J Dermatol; 2019 Aug; 181(2):385-386. PubMed ID: 30719708
[No Abstract] [Full Text] [Related]
8. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Liberman P; Shifera AS; Berkenstock M
Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
10. Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.
Szekely S; Vaccari D; Salmaso R; Belloni-Fortina A; Alaibac M
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):65-66. PubMed ID: 32490817
[No Abstract] [Full Text] [Related]
11. Successful use of dupilumab for the treatment of atopic dermatitis on the genitals, a neglected anatomical site.
Paolino G; Sernicola A; Di Nicola MR; Foti A; Brianti P; Vaira F; Grieco T; Mercuri SR
Clin Exp Dermatol; 2022 Jan; 47(1):176-178. PubMed ID: 34398987
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Caroppo F; Biolo G; Belloni Fortina A
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e368. PubMed ID: 32386431
[No Abstract] [Full Text] [Related]
13. Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series.
Da J; Ali K; Lu K; Lou H; Qiu Y; Shan J; Wu L
Clin Exp Dermatol; 2022 Feb; 47(2):423-425. PubMed ID: 34482550
[No Abstract] [Full Text] [Related]
14. Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.
Charvet E; Bourrat E; Hickman G; Donadieu J; Bellanné-Chantelot C; Jachiet M; Bouaziz JD; Bagot M; Cassius C
Clin Exp Dermatol; 2021 Oct; 46(7):1334-1335. PubMed ID: 33864281
[No Abstract] [Full Text] [Related]
15. Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
Gupta AK; Love RP; Abramovits W; Vincent KD
Skinmed; 2019; 17(2):107-109. PubMed ID: 31145061
[No Abstract] [Full Text] [Related]
16. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.
Blauvelt A; Rosmarin D; Bieber T; Simpson EL; Bagel J; Worm M; Deleuran M; Katoh N; Kawashima M; Shumel B; Chen Z; Rossi AB; Hultsch T; Ardeleanu M
Br J Dermatol; 2019 Jul; 181(1):196-197. PubMed ID: 30719707
[No Abstract] [Full Text] [Related]
17. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
18. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
19. Rosacea associated with dupilumab therapy.
Heibel HD; Hendricks AJ; Foshee JP; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
[No Abstract] [Full Text] [Related]
20. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
